Program
EDP-323
A development code. Also written as “EDP-323 Dose Regimen 1” and “EDP-323 Dose Regimen 2”.
Its studies are mostly in Respiratory Syncytial Virus Infections, led by Enanta Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Enanta Pharmaceuticals | 40 open or running | phase 2since Nov 27, 2023 | Oct 17, 2022 | none ahead |
Also a collaborator on its studies: hvivo-services-limited.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 17, 2022First study: phase 1 study in Respiratory Syncytial Virus InfectionsFirst studyNCT05587478 · 82 enrolled · United States
- Nov 27, 2023Phase 2 study in Respiratory Syncytial Virus InfectionsNCT06170242 · 142 enrolled · United Kingdom
- Feb 21, 2025Phase 1 study in Respiratory Syncytial Virus InfectionsNCT06847464 · 48 enrolled · United States
- Apr 1, 2025Phase 1 study in Respiratory Syncytial Virus InfectionsNCT06917508 · 24 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06917508Respiratory Syncytial Virus Infections · United States | 1 | Completed | Jun 6, 2025 | 24 |
| NCT06847464Respiratory Syncytial Virus Infections · United States | 1 | Completed | May 24, 2025 | 48 |
| NCT06170242Respiratory Syncytial Virus Infections · United Kingdom | 2 | Completed | Jun 17, 2024 | 142 |
| NCT05587478Respiratory Syncytial Virus Infections · United States | 1 | Completed | Mar 29, 2023 | 82 |
How it is read
Names in the registry
- “EDP-323”, 6 entries
- “EDP-323 Dose Regimen 1”, 1 entry
- “EDP-323 Dose Regimen 2”, 1 entry
Codes read as this program: EDP323.
Conditions, from the studies’ own filings
- Respiratory Syncytial Virus Infections, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.